[Testing of the bronchodilator NAB 365 in a double blind trial author's transl].
In a double blind trial NAD 365 (3 X 10 and 20 mug), Salbutamol (3 X 2,0 mg), and Terbutalin (3 X 2,5 mg) were compared for 14 days. In a total of 96 patients five parameters concerning function were tested-p02, pC02, airway resistance (Rt), intrathoracic gas volume (IGV), and forced expiratory flow. Although the doses for NAB 365 were considerably lower than those of the comparative substances, the degree of efficacy for NAB 365, Salbutamol and Terbutalin was the same. Adverse reactions of all three substances under consideration were negligible. The higher dose of NAB 365 showed the least favoralbe result in this respect.
D000403:Airway Resistance / Q000187:drug effects; D000420:Albuterol / Q000494:pharmacology; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001991:Bronchitis / Q000188:drug therapy* / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002245:Carbon Dioxide / Q000097:blood; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000097:blood; D010313:Partial Pressure; D010627:Phenethylamines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D010919:Placebos; D012119:Respiration / Q000187:drug effects; D013726:Terbutaline / Q000494:pharmacology
D001993:Bronchodilator Agents; D010627:Phenethylamines; D010919:Placebos; D002245:Carbon Dioxide; D013726:Terbutaline; D000420:Albuterol; D010100:Oxygen
Prüfung des Broncholytikums NAB 365 im Doppelblindversuch